188 related articles for article (PubMed ID: 11751504)
21. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
22. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
Berchuck A; Iversen ES; Lancaster JM; Pittman J; Luo J; Lee P; Murphy S; Dressman HK; Febbo PG; West M; Nevins JR; Marks JR
Clin Cancer Res; 2005 May; 11(10):3686-96. PubMed ID: 15897565
[TBL] [Abstract][Full Text] [Related]
23. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer.
Oshita F; Kameda Y; Ikehara M; Tanaka G; Yamada K; Nomura I; Noda K; Shotsu A; Fujita A; Arai H; Ito H; Nakayama H; Mitsuda A
Anticancer Res; 2002; 22(2B):1065-70. PubMed ID: 12168902
[TBL] [Abstract][Full Text] [Related]
25. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma.
Karczewska A; Nawrocki S; Breborowicz D; Filas V; Mackiewicz A
Cancer; 2000 May; 88(9):2061-71. PubMed ID: 10813718
[TBL] [Abstract][Full Text] [Related]
26. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer.
Psyrri A; Bamias A; Yu Z; Weinberger PM; Kassar M; Markakis S; Kowalski D; Efstathiou E; Camp RL; Rimm DL; Dimopoulos MA
Clin Cancer Res; 2005 Dec; 11(23):8384-90. PubMed ID: 16322299
[TBL] [Abstract][Full Text] [Related]
27. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma.
Shigemasa K; Gu L; O'Brien TJ; Ohama K
Clin Cancer Res; 2003 May; 9(5):1756-63. PubMed ID: 12738731
[TBL] [Abstract][Full Text] [Related]
28. AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients.
Davidson B; Goldberg I; Reich R; Tell L; Dong HP; Trope' CG; Risberg B; Kopolovic J
Gynecol Oncol; 2003 Aug; 90(2):248-57. PubMed ID: 12893184
[TBL] [Abstract][Full Text] [Related]
29. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
[TBL] [Abstract][Full Text] [Related]
30. Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma.
Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Yamakawa T; Morishita H; Terao T
Cancer; 2003 Jul; 98(2):424-30. PubMed ID: 12872365
[TBL] [Abstract][Full Text] [Related]
31. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
Davidson B; Shafat I; Risberg B; Ilan N; Trope' CG; Vlodavsky I; Reich R
Gynecol Oncol; 2007 Feb; 104(2):311-9. PubMed ID: 17030350
[TBL] [Abstract][Full Text] [Related]
32. Failure of BRCA1 dysfunction to alter ovarian cancer survival.
Buller RE; Shahin MS; Geisler JP; Zogg M; De Young BR; Davis CS
Clin Cancer Res; 2002 May; 8(5):1196-202. PubMed ID: 12006538
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer.
Gotlieb WH; Goldberg I; Weisz B; Davidson B; Novikov I; Kopolovic J; Ben-Baruch G
Gynecol Oncol; 2001 Jul; 82(1):99-104. PubMed ID: 11426969
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Piccinno R; Rigault de la Longrais IA; Howarth DJ; Diamandis EP
Clin Cancer Res; 2001 Aug; 7(8):2372-9. PubMed ID: 11489815
[TBL] [Abstract][Full Text] [Related]
35. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
36. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
[TBL] [Abstract][Full Text] [Related]
37. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
[TBL] [Abstract][Full Text] [Related]
38. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival.
Segawa T; Shozu M; Murakami K; Kasai T; Shinohara K; Nomura K; Ohno S; Inoue M
Clin Cancer Res; 2005 Mar; 11(6):2188-94. PubMed ID: 15788666
[TBL] [Abstract][Full Text] [Related]
39. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
[TBL] [Abstract][Full Text] [Related]
40. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
